Table 2.

Analysis methods and omics in endometrial cancer studies, including key findings.

Reference	Methods	Omics	Key Findings
Gao et al. [47]	bioinformatics, immunohistochemistry, cell-based assay, Western blot	genomics, transcriptomics, epigenomics, proteomics	TMEFF2 as target for early diagnosis and EC treatment
Geng et al. [48]	bioinformatics, cell-based assay, qPCR, Western blot	genomics, transcriptomics, proteomics	RNF183 as prognostic and early diagnostic indicator for EC
Geng et al. [49]	bioinformatics, cell-based assay, qPCR	genomics, transcriptomics, epigenomics proteomics	ZBTB7A as prognostic biomarker for EC
Li et al. [50]	bioinformatics, cell-based assay, qRT-PCR, Western blot	genomics, transcriptomics, epigenomics proteomics	BTG1 as prognostic biomarker for EC
Wan et al. [51]	bioinformatics, immunohistochemistry, cell-based assay, qPCR	genomics, transcriptomics, proteomics	HOXB9 is correlated with EC cell migration and promotes its progression
Zhang et al. [52]	immunohistochemistry, cell-based assay, qRT-PCR, Western blot	genomics, transcriptomics, proteomics	TTK as therapeutic target for EC
Zhang et al. [53]	bioinformatics, immunohistochemistry, cell-based assay, qPCR	genomics, transcriptomics, proteomics	ARF/ARL family genes as prognostic biomarkers for EC
Zou et al. [54]	bioinformatics, immunohistochemistry	genomics, transcriptomics, proteomics	LGR5, SST, ZNF558, and PTGDS participate in the development of EC; PTGDS as biomarker and therapeutic target for EC

TMEFF2, tomoregulin-2; RNF183, ring finger protein 183; ZBTB7A, zinc finger and BTB domain-containing protein 7A; BTG1, BTG anti-proliferation factor 1; HOXB9, homeobox B9; TTK, TTK protein kinase; ARF/ARL, ADP-ribosylation factor/ARF-like protein; LGR5, leucine-rich repeat-containing G-protein coupled receptor 5; SST, somatostatin; ZNF558, zinc finger protein 558; PTGDS, prostaglandin D2 synthase.